Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
← catalyst calendarSponsored by Bone Biologics Corp (industry) · BBLG — their whole pipeline →.
Phase
Not applicable
Status
Unknown status
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
30estimated
Sites
3
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-01 | estimated | When the study began enrolling |
| Primary completion | 2025-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2019-01-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Degenerative Disc Disease
- Spondylolisthesis
Intervention
- Device: NB1
Primary outcome
what the primary-completion date above is the date OFFusion
measured 12 months
Permalink · BBLG's whole pipeline · Catalyst calendar · Every registered study · What changed